Evidence map›Paper›PMID 22372739›Full record

ArticleBiomacromolecules2012

Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells.

Mohammad H El-Dakdouki, David C Zhu, Kheireddine El-Boubbou, Medha Kamat, Jianjun Chen, Wei Li, Xuefei Huang

Abstract read
In one paragraph

Article in Biomacromolecules, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 123 citations in OpenAlex.

  1. Iron-Based Nanoparticles as Delivery Tools.Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Article
  4. Endogenous HInternational journal of nanomedicine · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Glyconanomaterials for biosensing applications.Biosensors & bioelectronics · 2016
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mohammad H El-DakdoukiDepartment of Chemistry, Michigan State University, East Lansing, Michigan 48824, United States.
David C Zhu
Kheireddine El-Boubbou
Medha Kamat
Jianjun Chen
Wei Li
Xuefei Huang
Michigan State University · USUniversity of Tennessee Health Science Center · US

Funding

Virus-Like Particle Based Antigen Display as Multi-component Anticancer VaccinesR01CA149451 · NCI · MICHIGAN STATE UNIVERSITY · PI HUANG, XUEFEI · 2011 to 2015
$2.4M
Acquisition of a 400MHz Solution NMR System with an AutosamplerS10RR026377 · NCRR · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI · 2010 to 2010
$253k
NCI NIH HHS R01 CA149451NCRR NIH HHS S10 RR026377
6 · The paper itself

Abstract

Currently, there is high interest in developing multifunctional theranostic platforms for cancer monitoring and chemotherapy. Herein, we report hyaluronan (HA)-coated superparamagnetic iron oxide nanoparticles (HA-SPION) as a promising system for targeted imaging and drug delivery. When incubated with cancer cells, HA-SPIONs were rapidly taken up and the internalization of HA-SPION by cancer cells was much higher than the NPs without HA coating. The high magnetic relaxivity of HA-SPION coupled with enhanced uptake enabled magnetic resonance imaging of cancer cells. Furthermore, doxorubicin (DOX) was attached onto the nanoparticles through an acid responsive linker. While HA-SPION was not toxic to cells, DOX-HA-SPION was much more potent than free DOX to kill not only drug-sensitive but also multi-drug-resistant cancer cells. This was attributed to differential uptake mechanisms and cellular distributions of free DOX and DOX-HA-SPION in cancer cells.

Indexed as

Drug Delivery SystemsNanoparticlesAntibiotics, AntineoplasticCell Line, TumorCell SurvivalCoated Materials, BiocompatibleDiagnostic ImagingDose-Response Relationship, DrugDoxorubicinDrug Screening Assays, AntitumorFlow CytometryHumansHyaluronic AcidMicroscopy, ConfocalMolecular StructureNeoplasmsAntibiotics, AntineoplasticCoated Materials, BiocompatibleDoxorubicinHyaluronic Acid

Identifiers

PMID22372739
PMCPMC5475368
OpenAlexW2075277543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.